afatinib

You have access
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CHI-HAN CHEN, JOHN WEN-CHENG CHANG, CHING-FU CHANG, CHEN-YANG HUANG, CHENG-TA YANG, CHIH-HSI SCOTT KUO, YUEH-FU FANG, PING-CHIH HSU and CHIAO-EN WU

Anticancer Research April 2022, 42 (4) 2145-2157; DOI: https://doi.org/10.21873/anticanres.15697
You have access
First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
MI-HYUN KIM, CHANG MIN CHOI, SUNG YONG LEE, CHEOL KYU PARK, YOON SOO CHANG, KYE YOUNG LEE, SEUNG JOON KIM, SEI HOON YANG, JEONG SEON RYU, JEONG EUN LEE, SHIN YUP LEE, CHAN KWON PARK, SANG HOON LEE, SEUNG HUN JANG, SEONG HOON YOON and TAE WON JANG

Anticancer Research March 2022, 42 (3) 1615-1622; DOI: https://doi.org/10.21873/anticanres.15636
You have access
Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
MARTIN SVATON, MONIKA BRATOVA, ONDREJ FISCHER, JANA KREJCI, LEONA KOUBKOVA, MARKETA CERNOVSKA, MICHAL HRNCIARIK, MILADA ZEMANOVA, HELENA COUPKOVA, BEDRICH PORZER, DANIEL DOLEZAL, TANA TUZOVA, KAROLINA HURDALKOVA, MAGDA BARINOVA and JANA SKRICKOVA

Anticancer Research April 2021, 41 (4) 2059-2065; DOI: https://doi.org/10.21873/anticanres.14975
You have access
Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status
LENA HUBER, RICHARD BIRK, NICOLE ROTTER, CHRISTOPH ADERHOLD, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research February 2020, 40 (2) 825-835; DOI: https://doi.org/10.21873/anticanres.14014
You have access
Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells
SUSUMU NAKATA, MITSUGU FUJITA and HAYAO NAKANISHI

Anticancer Research November 2019, 39 (11) 5927-5932; DOI: https://doi.org/10.21873/anticanres.13797
You have access
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
MOTOHIRO TAMIYA, AKIHIRO TAMIYA, HIDEKAZU SUZUKI, KAZUNORI MORIIZUMI, KENJI NAKAHAMA, YOSHIHIKO TANIGUCHI, KEI KUNIMASA, MADOKA KIMURA, TAKAKO INOUE, HANAKO KUHARA, KAZUMI NISHINO, TOMONORI HIRASHIMA, SHINJI ATAGI, FUMIO IMAMURA and TORU KUMAGAI

Anticancer Research July 2019, 39 (7) 3923-3929; DOI: https://doi.org/10.21873/anticanres.13544
You have access
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
KUNIHIKO MIYAZAKI, TOMOHIRO TAMURA, TAKAYUKI KABURAGI, KAZUHITO SAITO, MASAHARU INAGAKI, TAKAAKI YAMASHITA, HIDEO ICHIMURA, TAKESHI NAWA, TAKEO ENDO, KENJI HAYASHIHARA, MASAKI KIMURA, KOICHI KURISHIMA, HIROYUKI NAKAMURA, KINYA FURUKAWA, NORIHIRO KIKUCHI, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research September 2018, 38 (9) 5409-5415; DOI: https://doi.org/10.21873/anticanres.12871
You have access
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
SATOSHI WATANABE, OU YAMAGUCHI, AI MASUMOTO, YURI MAENO, YOSUKE KAWASHIMA, OSAMU ISHIMOTO, SHUNICHI SUGAWARA, HIROHISA YOSHIZAWA, TOSHIAKI KIKUCHI, TOSHIHIRO NUKIWA and KUNIHIKO KOBAYASHI

Anticancer Research August 2018, 38 (8) 4699-4704; DOI: https://doi.org/10.21873/anticanres.12776
You have access
Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src
BENEDIKT KRAMER, MARCEL KNEISSLE, RICHARD BIRK, NICOLE ROTTER and CHRISTOPH ADERHOLD

Anticancer Research May 2018, 38 (5) 2723-2731;
You have access
Skin Rash Can Be a Useful Marker for Afatinib Efficacy
SHINGO NASU, HIDEKAZU SUZUKI, TAKAYUKI SHIROYAMA, AYAKO TANAKA, KAORI IWATA, NORIKO RYOTA, YUKI UEDA, SO TAKATA, KENTARO MASUHIRO, SATOMU MORITA, NAOKO MORISHITA, NORIO OKAMOTO and TOMONORI HIRASHIMA

Anticancer Research March 2018, 38 (3) 1783-1788;

Main menu

User menu

Search

afatinib

Pages